DRUGS ARE GETTING COSTLY- IS VALUE BASED REIMBURSEMENT THE ANSWER?
Selected topics and opinions from our studies
PRESCRIPTION DRUG INDUSTRY
EVALUATION •RESEARCH •ANALYSIS • EDUCATION
MEANT FOR REAL-LIFE DECISIONS
RxMarketSCIENCE studies the industry developments-whether it is a regulatory change, political turn, major acquisition, major corporate news and other industry dynamics that affect the pharmaceutical business eco-system. We share some of our thoughts and opinions on these developments here. We also share our thoughts on theoretical underpinnings of the industry periodically. While these high level information may not give you an immediate reason to act on, it should give you to good sense of the possible impact on your decisions (or potential decisions) when certain events takes place in the industry. Please note that we are not making any investment advice and we are not investment advisors. These are our informed opinions only. Readers must do their own analysis specific to their context and needs before making any decision based on our opinions.